Lejia Regenerative Technology Co.

What Lejia Regenerative Technology Co. does

Lejia Regenerative Technology Co. (樂迦再生科技股份有限公司, branded "Locus Cell") is a Taiwan-based, publicly listed cell therapy Contract Development and Manufacturing Organization (CDMO) incorporated on October 15, 2020 and listed on Taiwan's Emerging Stock Board (stock code 6891) since April 29, 2022. The company was established in 2019 as a joint venture between Hitachi Group and Sanegu Corporation with NT$2 billion in first-round financing, with the National Development Fund subsequently becoming the largest public shareholder. Lejia serves domestic Taiwanese and international biotech and pharmaceutical companies that need to outsource PIC/S GMP-compliant manufacturing of cell-based therapies, including iPSC-derived products, CAR-T therapies, exosomes, and myocardial cell sheets.

Its core technology stack centers on iPSC standardization and mass production (backed by an exclusive July 2024 license to Kyoto University's iPSC patents, which the company claims can reduce cell therapy production costs to roughly one-tenth of conventional methods), CAR-T manufacturing (trial-manufacturing completed December 2023), INCI-certified iPSC exosome products for cosmetics (certified November 2023), CellFiber's high-efficiency cell encapsulation technology, and co-developed third-generation myocardial cell sheets with Sanegu. The platform is designed to integrate automated, digitalized, and intelligent manufacturing compliant with PIC/S GMP.

Lejia makes money through two primary revenue streams: (1) CDMO services — project-based, quote-based contract manufacturing for iPSC, CAR-T, and exosome products at its current Taipei-area facilities and, once complete, the NT$7 billion Zhubei Smart GMP facility in the Hsinchu Biomedical Science Park (24 cell operation rooms, ~19,800 sqm, 98.43% construction-complete as of November 15, 2025; production targeted for 2026); and (2) technology licensing — royalties and licensing fees from its iPSC patent estate, including the Kyoto University license. Distribution is B2B-direct via enterprise field sales, supplemented by event-driven outreach at industry conferences (Bio Asia Taiwan, BWT2025, Taiwan Healthcare Expo) and strategic channel partnerships with Hitachi, Minaris, CellFiber, and Yokohama CM Plus for Japan and Southeast Asia. YTD 2025 revenue (Jan–Nov) was NT$11.787 million, consistent with a pre-revenue / early-revenue stage ahead of Zhubei commissioning.

Name

Lejia Regenerative Technology Co.

Legal name

樂迦再生科技股份有限公司

Website

https://locus-cell.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Lejia Regenerative Technology Co. (Locus Cell) is a Taiwan-based, publicly listed cell therapy CDMO building Asia's largest automated PIC/S GMP cell manufacturing facility in Zhubei; it provides contract iPSC, CAR-T, exosome, and myocardial cell sheet manufacturing and licensing to biotech and pharmaceutical clients in Taiwan, Japan, Southeast Asia, and the US.

Ownership category

akta.pro rank

Product category

Cell Therapy CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy CDMO (HLAGABAD), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• Cell therapy CDMO
• IPSC technology
• Regenerative medicine
• CAR-T manufacturing
• GMP cell production

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. CDMO Services (Cell Therapy Manufacturing): Lejia provides contract development and manufacturing services for cell therapy products including iPSC, CAR-T, and exosome-based products. Clients include domestic and international biotech companies that outsource cell manufacturing to Lejia's PIC/S GMP facility.
2. Technology Licensing (iPSC Patent): Lejia generates revenue through licensing of iPSC technology, including patents licensed from Kyoto University. The company secured international iPSC patent authorization from Kyoto University in July 2024.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Lejia Regenerative Technology (Locus Cell) is a cell therapy Contract Development and Manufacturing Organization (CDMO) that provides process development, scale-up, and GMP manufacturing services for cell and gene therapy products, with proprietary iPSC (induced pluripotent stem cell), CAR-T, and exosome platforms. The company operates a Zhubei Smart GMP Facility and supplies iPSC-derived exosome raw materials certified under INCI for cosmetic applications, while co-developing regenerative products such as myocardial cell sheets.

Product overview

Lejia Regenerative Technology Co. operates as a cell therapy CDMO (Contract Development and Manufacturing Organization) providing integrated services across the cell therapy value chain. The company's core offerings include iPSC technology platform for standardized cell mass production, iPSC exosome products with INCI certification for cosmetics applications, CAR-T therapy development services, and myocardial cell sheet products. The company is building the Asia's largest automated cell manufacturing factory in Zhubei Biomedical Park, targeting to become the leading cell therapy CDMO in Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell Therapy CDMO Services

Quantifiable outcome

• iPSC technology standardization enables mass production with costs potentially reduced to one-tenth of conventional methods
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Ten partnerships are on record, tiered core, supporting and minor.

• Cambium BiocoreStrategic or Co-development Partner · 23 October 2025Lejia's Zhubei Smart GMP Facility secured its first international Phase III CDMO manufacturing MOU with Cambium Bio. This partnership targets the US$900 million dry eye disease market, marking Lejia's entry into international late-stage clinical manufacturing.
• Yokohama CM Plus Corporation (橫濱CM Plus株式會社)coreStrategic or Co-development Partner · 23 October 2025Lejia, San Gu (三顧), and Yokohama CM Plus Corporation signed a trilateral cooperation MOU to jointly promote Taiwan-Japan regenerative medicine collaboration. The partnership leverages Taiwan's manufacturing advantages and Japan's regenerative medicine expertise.
• CellFiber Co., Ltd.coreTechnology or Integration · 30 June 2025Lejia partnered with CellFiber (Japan) to implement high-efficiency cell encapsulation expansion culture technology. The partnership generated over NT$10 million in CDMO orders, representing a new model for Taiwan-Japan biotech cooperation. CellFiber's CEO, Dr. Furushige Kazuchika (古石和親), serves as an advisor to Lejia.
• Okta Identity Cloud (奧登/Okta)supportingTechnology or Integration · 6 December 2024Lejia partnered with Augtin (奧登) to implement Okta Identity Cloud solutions for information security management, protecting sensitive data across its CDMO operations.
• Kyoto University (日本京都大學)coreTechnology or Integration · 2 July 2024Lejia obtained iPSC patent licensing authorization from Kyoto University in July 2024, marking the first step in its international market expansion. This licensing agreement enables Lejia to manufacture and commercialize iPSC-based cell therapy products using Kyoto University's proprietary technology.
• MediSixminorStrategic or Co-development Partner · 12 June 2024Lejia formed an alliance with MediSix, a company backed by Temasek (淡馬錫), to co-develop CAR-T therapies. This partnership was announced in June 2024 and reflects Lejia's strategy to expand into Singapore and broader Southeast Asian markets.
• Taiwan Cloud AI (台智雲)supportingTechnology or Integration · 3 December 2023Lejia partnered with Taiwan Cloud AI to strengthen its digital infrastructure and information security capabilities. This collaboration supports the company's CDMO digitalization and AI-driven manufacturing optimization initiatives.
• Minaris Regenerative Medicine (Minaris公司)coreTechnology or Integration · 18 August 2023Lejia deepened its partnership with Minaris, the world's #1 cell therapy CDMO by market share. Minaris provides technology transfer and expertise to help Lejia assist domestic CAR-T companies in entering international markets. Lejia's advisor Dr. Furushige Kazuchika is the former CEO of Minaris.
• Dr. Dario CampanasupportingOthers · 21 February 2023Dr. Dario Campana, a globally recognized CAR-T cell therapy expert and inventor of Novartis's CAR-T technology, serves as Lejia's Chief Scientific Advisor. He also facilitated a meeting between Lejia and Taiwan's Vice President Lai Ching-de.
• Hitachi (日立化成/Hitachi Chemical)coreTechnology or Integration · 17 April 2019Hitachi (through its subsidiary Hitachi Chemical) partnered with San Gu to establish Lejia in 2019, with NT$20 billion in first-round financing. Hitachi provides cell manufacturing technology and expertise to build Lejia's PIC/S GMP facility. Taiwan Hitachi Asia Pacific (台灣日立亞太) is also a board member.

Scale indicators10 records

Recent moves11 records

Expansion highlights6 records

Emerging players

• Cellares: US-based emerging cell therapy manufacturing automation company building automated, closed-system cell therapy manufacturing platforms. Comparable to Lejia's Zhubei automated facility ambition and cell therapy CDMO automation thesis.
• RoosterBio: US-based cell therapy manufacturing platform company focused on MSC and other cell types with standardized production processes. Comparable to Lejia in addressing cell therapy manufacturing scalability and cost.
• Pluristem Therapeutics: Cell therapy developer using placenta-derived cell products, relevant as a comparable emerging cell therapy player that relies on contract manufacturing infrastructure for scale-up of allogeneic cell therapies.

Broad incumbents

• AGC Biologics: Global CDMO with cell and gene therapy manufacturing services and mammalian cell culture expertise. Operates at a broader scale than Lejia across multiple modalities, including cell therapy manufacturing.
• Lonza: Global leader in CDMO services for biologics and cell/gene therapies with established mammalian cell manufacturing capacity. Competes broadly with Lejia in cell therapy CDMO and provides a benchmark for incumbent scale and customer breadth.
• Catalent: Major global CDMO with cell therapy and gene therapy capabilities across multiple sites. Provides large-scale, established alternatives for biotech clients outsourcing cell-based product manufacturing, overlapping with Lejia's CDMO offering.
• Showa Denko Materials (Resonac): Successor entity to Hitachi Chemical, which was Lejia's founding Japanese partner. Operates a cell therapy CDMO business (formerly Hitachi Chemical's regenerative medicine unit), directly comparable in cell therapy manufacturing focus.

Regional players

• MEDINET: Japanese cell therapy contract manufacturer and service provider. Comparable to Lejia in cell therapy CDMO focus and Japanese customer base, but operates primarily in Japan rather than the broader Asia-Pacific market.

Direct peers

• Minaris Regenerative Medicine: World's #1 cell therapy CDMO by market share, headquartered in Japan. Directly comparable to Lejia as a cell therapy contract manufacturer; Minaris is also Lejia's technology partner and its former CEO serves as Lejia's corporate advisor.

Others

• Center for iPS Cell Research and Application (CiRA), Kyoto University: Academic center of excellence in iPSC technology led by Shinya Yamanaka. Lejia has licensed iPSC patents from Kyoto University; CiRA represents both a critical IP source and a scientific benchmark for iPSC-derived therapy development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/locus-cell

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lejia Regenerative Technology Co.